Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.

"data sharing provision has been made for the study. this article has an editorial commentary: https://doi"

"Conflict of interest: I. Campo, B.C. Trapnell and B.C. Carey serve as investigators on another clinical trial of inhaled rGM-CSF therapy of autoimmune PAP. B.C. Trapnell and B.C. Carey have served as consultants regarding the development of inhaled rGM-CSF as therapy of aPAP. No other authors have no financial or other conflicts of interest to declare related to this work."

"Support statement: This trial was supported by the Agenzia Italiana del Farmaco (FARM7MCPK4 to M. Luisetti), Italy. B.C. Trapnell and B.C. Carey were supported by grants from the National Heart, Lung, and Blood Institute (R01 HL085453 to B.C. Trapnell) and Translational Pulmonary Science Center and Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center. Funding information for this article has been deposited with the Crossref Funder Registry."

"This study is registered at ClinicalTrials.gov with identifier number NCT00901511. No data sharing provision has been made for the study."